ABCL
AbCellera Biologics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ABCL
Abcellera Biologics Inc.
A Canadian provider of drug discovery platform that designed to develop next-generation antibody therapies
Biological Technology
11/08/2012
12/11/2020
NASDAQ Stock Exchange
596
12-31
Common stock
150 W 4th Avenue, Vancouver, BC V5Y 1G6
--
AbCellera Biologics Inc., was incorporated and commenced business activities on November 8, 2012 under the British Columbia Business Companies Act. The company is engaged in the business of combining a variety of complex technologies in its medical research and development to discover antibody drugs faster, cheaper and more efficiently. Since its inception, the company has been committed to R&D activities to support its current partner projects and future platform development efforts.
Earnings Call
Q1/2025
Estimate EPS-0.14
Actual EPS-0.14
Estimate Revenue7.31M
Actual Revenue4.24M
AbCellera Biologics Q1 2025: Strategic Shifts and Contradictions in Partnerships, Validation, and Preclinical Timelines
May 19,2025 11:34
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.16
Actual EPS-0.12
Estimate Revenue6.36M
Actual Revenue17.08M
AbCellera's Q2 2025 Earnings Call: Unpacking Contradictions in Regulatory Focus, Dosing Strategies, and Market Expansion
Aug 10,2025 06:10
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ABCL has released its 2025 Q3 earnings. EPS was reported at -0.19, versus the expected -0.16, missing expectations. The chart below visualizes how ABCL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ABCL has released its 2025 Q3 earnings report, with revenue of 8.96M, reflecting a YoY change of 37.62%, and net profit of -57.12M, showing a YoY change of -11.76%. The Sankey diagram below clearly presents ABCL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
